Találati lista | Tudóstér

001-es BibID:	BIBFORM073148
Első szerző:	Daróczi Borbála (orvos)
Cím:	Post-operative management of primary glioblastoma multiforme in patients over 60 years of age / Borbála Daróczi, Erika Szántó, Judit Tóth, Pál Barzó, László Bognár, Gyula Bakó, János Szántó, Petra Mózes, Katalin Hideghéty
Dátum:	2013
ISSN:	0019-1442
Megjegyzések:	BACKGROUND AND PURPOSE:Optimal treatment for elderly patients with glioblastoma multiforme is not well defined. We evaluated the efficacy of post-operative radiotherapy with or without concomitant and/or adjuvant temozolomide in patient, aged > or = 60 years to assess survival and identify prognostic factors of survival.METHODS:A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged > or = 60 years treated with post-operative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions. Prognostic factors were determined by univariate and multivariate analyses.RESULTS:Of 75 study participants (54.7% male; median age at first diagnosis, 65.1 years), 29 (38.7%) underwent gross total resection, whereas others underwent partial resection or biopsy only. All but 1 patient received radiotherapy. Twenty patients received concomitant temozolomic e only. Adjuvant temozolomide (1-50 cycles) was administered in 42 patients; 16 received > or = 6 cycles. Median overall survival was 10.3 months. One- and 2-year overall survival rates were 42.6% and 6.7%, respectively. Median progression-free survival was 4.1 months. Radiochemotherapy was generally well tolerated. Median overall survival was 15.3 and 29.6 months for patients who received 6-12 cycles and >12 cycles of adjuvant temozolomide, respectively. There were no significant differences in overall survival between age groups (60-64, 65-69, and > or = 70 years). Adjuvant temozolomide, Karnofsky performance status > or = 70, and additional surgery after progression were significant prognostic factors of longer overall survival (p<0.05).CONCLUSIONS:Radiochemotherapy, including > or = 6 cycles of adjuvant temozolomide, was safe and prolonged survival of glioblastoma patients aged > or = 60 years. Aggressive therapy should not be withheld from patients aged > or = 60 years with good performance status because of age.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény hazai lapban adjuváns idősek glioblastoma idegsebészet radiokemoterápia
Megjelenés:	Ideggyógyászati Szemle 66 : 11-12 (2013), p. 391-398. -
További szerzők:	Szántó Erika (1985-) (orvos) Tóth Judit Barzó Pál Bognár László (1958-) (idegsebész, gyermekidegsebész) Bakó Gyula (1951-) (belgyógyász) Szántó János Mózes Petra Hideghéty Katalin
Pályázati támogatás:	75833 OTKA
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: